WO2011011453A3 - Phenotyping tumor-infiltrating leukocytes - Google Patents

Phenotyping tumor-infiltrating leukocytes Download PDF

Info

Publication number
WO2011011453A3
WO2011011453A3 PCT/US2010/042654 US2010042654W WO2011011453A3 WO 2011011453 A3 WO2011011453 A3 WO 2011011453A3 US 2010042654 W US2010042654 W US 2010042654W WO 2011011453 A3 WO2011011453 A3 WO 2011011453A3
Authority
WO
WIPO (PCT)
Prior art keywords
infiltrating leukocytes
tumor
phenotyping
tumor infiltrating
immune signature
Prior art date
Application number
PCT/US2010/042654
Other languages
French (fr)
Other versions
WO2011011453A2 (en
Inventor
Lisa M. Coussens
David G. Denardo
Donal J. Brennan
Original Assignee
The Regents Of The University Of California
University College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, University College Dublin filed Critical The Regents Of The University Of California
Priority to EP10802804A priority Critical patent/EP2457096A4/en
Priority to AU2010276324A priority patent/AU2010276324A1/en
Publication of WO2011011453A2 publication Critical patent/WO2011011453A2/en
Publication of WO2011011453A3 publication Critical patent/WO2011011453A3/en
Priority to US13/314,072 priority patent/US20120329878A1/en
Priority to US14/044,715 priority patent/US20140100188A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer patient.
PCT/US2010/042654 2009-07-20 2010-07-20 Phenotyping tumor-infiltrating leukocytes WO2011011453A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP10802804A EP2457096A4 (en) 2009-07-20 2010-07-20 Phenotyping tumor-infiltrating leukocytes
AU2010276324A AU2010276324A1 (en) 2009-07-20 2010-07-20 Phenotyping tumor-infiltrating leukocytes
US13/314,072 US20120329878A1 (en) 2009-07-20 2011-12-07 Phenotyping tumor-infiltrating leukocytes
US14/044,715 US20140100188A1 (en) 2009-07-20 2013-10-02 Phenotyping tumor-infiltrating leukocytes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22703509P 2009-07-20 2009-07-20
US61/227,035 2009-07-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/314,072 Continuation-In-Part US20120329878A1 (en) 2009-07-20 2011-12-07 Phenotyping tumor-infiltrating leukocytes

Publications (2)

Publication Number Publication Date
WO2011011453A2 WO2011011453A2 (en) 2011-01-27
WO2011011453A3 true WO2011011453A3 (en) 2011-06-03

Family

ID=43499634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042654 WO2011011453A2 (en) 2009-07-20 2010-07-20 Phenotyping tumor-infiltrating leukocytes

Country Status (3)

Country Link
EP (1) EP2457096A4 (en)
AU (1) AU2010276324A1 (en)
WO (1) WO2011011453A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649205A4 (en) * 2010-12-07 2014-05-14 Univ California Phenotyping tumor-infiltrating leukocytes
MX2019014288A (en) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articles of manufacture and methods related to toxicity associated with cell therapy.
AU2022238685A1 (en) * 2021-03-19 2023-09-21 Artur MEZHEYEUSKI Novel biomarker

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BETTINA, S. ET AL.: "A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years.", GYNECOLOGIC ONCOLOGY, vol. 108, 2008, pages 106 - 111, XP022413053 *
BYERS, R. J. ET AL.: "Clinical quantitation of immune isgnature in follicular lymphoma by RT-PCR-based gene expression profiling.", BLOOD, vol. 111, 2008, pages 4764 - 4770, XP008151181 *
FIRAS, F. ET AL.: "The predictive value of CDB, CD4, CD68 and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.", CANCER, vol. 104, 2005, pages 1246 - 1254, XP008151180 *
KERR, K. M. ET AL.: "Partial regression in primary carcinoma of the lung: does it occur?.", HISTOPATHOL., vol. 33, no. 1, 1998, pages 55 - 63, XP008151232 *
See also references of EP2457096A4 *

Also Published As

Publication number Publication date
EP2457096A2 (en) 2012-05-30
EP2457096A4 (en) 2013-01-02
WO2011011453A2 (en) 2011-01-27
AU2010276324A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
IL254062B (en) Kits comprising anti-ptk7 antibody and use thereof in treating, detecting, diagnosing, or monitoring cancer
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
MX2019004193A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer.
IL254664A0 (en) Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
PH12016501206A1 (en) The use of inhibitors of bruton`s tyrosine kinase (btk)
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2012158780A3 (en) Lung cancer signature
MX346973B (en) Tumor specific antibodies and uses therefor.
MX2013008367A (en) Colon cancer gene expression signatures and methods of use.
MX2020009704A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer.
EP2652506A4 (en) The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer
WO2014011489A3 (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease
CA2888908A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2010054377A3 (en) Fully human antibodies against n-cadherin
EP2331711A4 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
MX2013015146A (en) Predictive biomarker of survival in the treatment of renal cell carcinoma.
WO2009003082A3 (en) Immunological compositions as cancer biomarkers and/or therapeutics
MX2016005854A (en) Neuregulin allosteric anti-her3 antibody.
WO2011011453A3 (en) Phenotyping tumor-infiltrating leukocytes
EP2473854A4 (en) Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
EP2455102A4 (en) Cancer therapeutic agent comprising antibody against cancer-specific membrane antigen
WO2011145085A3 (en) Novel antibodies and methods of use for the treatment and diagnosis of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10802804

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010276324

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010276324

Country of ref document: AU

Date of ref document: 20100720

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010802804

Country of ref document: EP